Alprazolam 2 mg tablets recalled due to potential manufacturing cross-contamination
Direct Rx is recalling Alprazolam C-IV 2 mg tablets (NDC 72189-121-60) due to potential cross-contamination at the manufacturer. Nine bottles distributed nationwide; affected lots include 03FE2319 and 13MY2217.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II precautionary recall with no reported illnesses, injuries, or deaths. The potential cross-contamination hazard is theoretical and unconfirmed, meeting criteria for Score 2 (Moderate) voluntary precautionary recalls.
Plain-English summary
Direct Rx is recalling Alprazolam C-IV 2 mg tablets (NDC 72189-121-60) due to potential product cross-contamination at the manufacturer. The company identified Current Good Manufacturing Practice (CGMP) deviations that posed a cross-contamination risk.
The recalled product was distributed nationwide. The recall involves 9 bottles with lot numbers 03FE2319 (Expiration 2/28/25) and 13MY2217 (Expiration 5/31/23).
Patients and healthcare providers who may have the affected product should verify the lot number and NDC number to determine if their medication is included in this recall.
The recalled product
- Product
- Alprazolam C-IV, 2 mg, 60 Tabs per bottle, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534, NDC 72189-121-60.
- Manufacturer
- Direct Rx
- Category
- Drug — Benzodiazepine
- Hazard
- cross-contamination
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: 03FE2319 Exp. 2/28/25
- 13MY2217 Exp. 5/31/23
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27